News

Coave raises $25M ahead of pivotal retinal gene therapy trial

Coave Therapeutics has added €21.2 ($25.0 million) million to its series B round, setting the French biotech up to move a gene therapy against PDE6b inherited retinal dystrophies toward pivotal trials.

In November 2017, Paris-based Coave, formerly known as Horama, took a therapy designed to deliver a nonmutated copy of the PDE6B gene to retinitis pigmentosa patients into a phase 1/2 clinical trial. The following year, led by Christine Placet, who took Trophos to its $470 million acquisition by Roche, Coave raised a series B round to support further development of the lead candidate.

Now, Coave, led by new CEO Rodolphe Clerval, has disclosed a €21.2 million expansion of the series B. Coave said the expansion brings the total raised up to €33.1 million, although in 2018 it put the value of the initial close of the series B round at €22.5 million.

Read full article here

Via fiercebiotech.com

Other (News) Articles

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.